News

The deal is part of Cipla’s front-end strategy and will expedite its product registrations in Brazil. Subject to certain closing deliverables, the transaction is expected to be completed

The company’s lead compound, cabozantinib, inhibits the activity of multiple tyrosine kinases including MET, VEGFRs and RET. Currently, cabozantinib is being evaluated in an ongoing Phase III METEOR

The trial showed that WM patients treated with Imbruvica experienced sustained disease control with an overall response rate (ORR) of 91% after a median of 19.1 months of

Development of the LIMITX is currently being supported by a grant from the National Institute on Drug Abuse of the National Institutes of Health (NIH) to develop an

If approved, lifitegrast has the potential to be the first treatment indicated to address both signs and symptoms of the disease. Lifitegrast is a new small-molecule integrin inhibitor

Relamorelin is Rhythm’s Phase II ghrelin agonist being developed for the treatment of diabetic gastroparesis and gastrointestinal (GI) functional disorders. Ghrelin is a peptide hormone produced in the

TCON is focused on the development and commercialization of new targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases. The agreement strengthens intellectual property estate around TRC102

The company intends to begin a Phase I trial in the second quarter of 2015 to evaluate the safety and tolerability of AGT-181 in adult patients with mucopolysaccharidosis

The FDA concluded that Perrigo’s products are therapeutically equivalent to Mallinckrodt’s Exalgo (hydromorphone HCI extended-release tablets) 8mg, 12mg and 16mg. According to the agency these products can be